Key PointsQuestionWhat is the clinical activity and safety of combination therapy of niraparib plus pembrolizumab in patients with platinum-based chemotherapy–resistant ovarian carcinoma or those not eligible for retreatment with a platinum-based chemotherapy? FindingsSixty-two patients with ovarian carcinoma were enrolled in this open-label, single-arm phases 1 and 2 study. Among the 60 evaluable patients, 3 had complete responses, 8 had partial responses, and 28 had stable disease. MeaningCombination niraparib plus pembrolizumab therapy showed promising antitumor activity in patients with ovarian carcinoma, warranting further investigation.
JAMA Oncology – American Medical Association
Published: Aug 13, 2019